Prodotto aggiunto correttamente al carrello.

discount label
H-CVNGVCWTV-OH
Visualizzare in 3D

Biosynth logo

H-CVNGVCWTV-OH

Rif. 3D-PP43783

1mg
217,00 €
10mg
253,00 €
100mg
455,00 €
Consegna stimata in Stati Uniti, il Venerdì 27 Dicembre 2024

Informazioni sul prodotto

Nome:
H-CVNGVCWTV-OH
Sinonimi:
  • NH2-Cys-Val-Asn-Gly-Val-Cys-Trp-Thr-Val-OH
Descrizione:

Peptide H-CVNGVCWTV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-CVNGVCWTV-OH include the following: The impairment of CD8 responses limits the selection of escape mutations in acute hepatitis C virus infection S Urbani, B Amadei, E Cariani, P Fisicaro - The Journal of , 2005 - journals.aai.orghttps://journals.aai.org/jimmunol/article/175/11/7519/36899 Influence of transmitted virus on the host's immune response: a case study S Merani, M Lucas , P Deshpande, K Pfafferott - Viral , 2017 - liebertpub.comhttps://www.liebertpub.com/doi/abs/10.1089/vim.2017.0001 Frequency and functional analysis of variants of the immunodominant epitope NS3-1073: Relevance for vaccine design P Fytili, G Dalekos, M Cornberg - Zeitschrift fur , 2006 - thieme-connect.comhttps://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-950788 Sequence-based in silico analysis of well studied Hepatitis C Virus epitopes and their variants in other genotypes (particularly genotype 5a) against South African N Prabdial-Sing, AJ Puren , SM Bowyer - BMC immunology, 2012 - Springerhttps://link.springer.com/article/10.1186/1471-2172-13-67 Molecular footprints reveal the impact of the protective HLA-A* 03 allele in hepatitis C virus infection K Fitzmaurice , D Petrovic , N Ramamurthy, R Simmons - Gut, 2011 - gut.bmj.comhttps://gut.bmj.com/content/60/11/1563.short Antigen-specific oral tolerance for the treatment of inflammatory and allergic diseases IL Huibregtse - 2009 - dare.uva.nlhttps://dare.uva.nl/document/2/63753 Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells H Wedemeyer , E Mizukoshi, AR Davis - Journal of , 2001 - Am Soc Microbiolhttps://journals.asm.org/doi/abs/10.1128/jvi.75.23.11392-11400.2001 Viral immunogenic footprints conferring T cell cross-protection to SARS-CoV-2 and its variants EC Antonio, MR Meireles, MAS Bragatte - Frontiers in , 2022 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.931372 Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV E Mizukoshi, C Eisenbach, BR Edlin - The Journal of , 2008 - academic.oup.comhttps://academic.oup.com/jid/article-abstract/198/2/203/808992 Structural in silico analysis of cross-genotype-reactivity among naturally occurring HCV NS3-1073-variants in the context of HLA-A* 02: 01 allele DA Antunes , MM Rigo , JP Silva, SP Cibulski - Molecular , 2011 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0161589011001131 Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans C Kelly, L Swadling , S Capone, A Brown - , 2016 - Wiley Online Libraryhttps://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.28294 Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes C Kelly, L Swadling , A Brown, S Capone - European journal of , 2015 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.201444686 Acute hepatitis C: to treat or not to treat? BA Piasecki, KR Reddy , KM Chang - Hepatology, 2002 - Wiley Online Libraryhttps://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.510350631 Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation A Lawal, C Basler, A Branch, J Gutierrez - American Journal of , 2004 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-6143.2004.00564.x Viral crosstalk: Who gets to say what first? A Cerny - Hepatology, 2002 - journals.lww.comhttps://journals.lww.com/hep/citation/2002/06000/Viral_crosstalk__Who_gets_to_say_what_first_.32.aspx

Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Biosynth
Conservazione lunga:
Note:

Proprietà chimiche

MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:

Informazioni sui pericoli

Numero ONU:
EQ:
Classe:
Indicazioni di pericolo:
Consigli di prudenza:
Vietato trasportare in aereo:
Informazioni sui pericoli:
Gruppo di imballaggio:
LQ:

Richiesta tecnica su: 3D-PP43783 H-CVNGVCWTV-OH

Si prega di utilizzare piuttosto il carrello per richiedere un preventivo o un ordine

Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.

* Campi obbligatori
Benvenuto su CymitQuimica!Utilizziamo i cookie per migliorare la tua visita. Non includiamo pubblicità.

Consulta la nostra Politica sui Cookie per maggiori dettagli o regola le tue preferenze in "Configura".